Generics news from FierceBiotech
NewsReport: Pfizer makes counter-offer for Ranbaxy
Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...
> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
Spectrum sells off generic drugs
Specturm Pharmaceuticals has sold its abbreviated NDAs for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Read more...
ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
> Jim Reddoch, a biotech analyst with Friedman, Billings & Ramsey, is raising some interesting questions about Genentech's second-generation Read more...
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
ALSO NOTED: US Oncology's CFO retires; Profits rise at Novartis, Merck, Lilly; and much more...
> US Oncology's CFO Rick McCook is resigning to explore opportunities in a retail or manufacturing business. Read more...
ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...
> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At Read more...
Can Big Pharma effectively develop new drugs?
When it comes to drug development, is bigger really better? That is the question Borje Eckholm, president and CEO of Investor AB--and one of AstraZeneca's biggest shareholders--poses in the London Read more...
| Press ReleasesPRESS RELEASE: CRESTOR ANDA CRESTOR ANDA On 30th October 2007, AstraZeneca received a notice-letter from Cobalt Pharmaceuticals, Inc. (“Cobalt”) notifying AstraZeneca Pharmaceuticals LP, AstraZeneca AB, IPR Pharmaceuticals Read more... PRESS RELEASE: FDA Announces Initiative to Bolster Generic Drug Program FDA Announces Initiative to Bolster Generic Drug Program Effort will streamline generic drug approval process; provide more options for consumers, health professionals The U.S. Food and Drug Read more... PRESS RELEASE: US federal appeals court temporarily stops Teva from selling its generic version of fAMVIR US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir US Court of Appeals for the Federal Circuit issues order prohibiting Teva from Read more... PRESS RELEASE: Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets; Novartis’ Motion for Preliminary Injunction Denied JERUSALEM, Israel--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) Read more... |
Get more Generics coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets